Sign in

You're signed outSign in or to get full access.

Martha J. Demski

Director at Alpha Teknova
Board

About Martha J. Demski

Martha J. Demski, age 72, is an independent Class I director of Alpha Teknova (TKNO), serving since August 31, 2023; she stands for re‑election in 2025 to a term ending in 2028 . She chairs the Audit Committee, serves on the Compensation Committee, and is designated an “Audit Committee financial expert”; the board has determined she is independent under SEC and Nasdaq rules . Her background includes extensive strategic and operational leadership in biotech and finance, with executive experience as a CFO and COO and public company board roles including chair, lead independent director, audit chair, and compensation committee member .

External Roles

CompanyExchange/TickerRole(s)Notes
Chimerix, Inc.NASDAQ: CMRXDirector (historical service noted); roles across companies have included chair, lead independent director, audit chair, and compensation committee memberAs disclosed by TKNO in nominee biography; specific dates not provided
Equillium, Inc.NASDAQ: EQDirector (historical service noted)As disclosed by TKNO; specific dates not provided
ADMA Biologics, Inc.NASDAQ: ADMADirector (historical service noted)As disclosed by TKNO; specific dates not provided

Board Governance

ItemDetail
Board class/tenureClass I; Director since 2023; current term expires 2025; nominated for term ending 2028
IndependenceIndependent under SEC/Nasdaq rules
CommitteesAudit Committee (Chair) and Compensation Committee (Member)
Audit expertiseDesignated “Audit Committee financial expert”
Meeting activityBoard held 9 meetings in FY2024; each director attended at least 75% of board+assigned committee meetings
Audit Committee activityAudit Committee held 5 meetings in FY2024; issued Audit Committee Report recommending inclusion of audited financials in the 2024 Form 10‑K
Governance contextTKNO is a Nasdaq “controlled company” (majority-owned by THP) and uses certain exemptions; Compensation Committee is not composed entirely of independent directors; Audit Committee remains fully independent as required

Fixed Compensation

Element (Non-Employee Director)AmountBasis/Notes
Annual Board retainer (cash)$40,000 Paid quarterly in arrears
Audit Committee Chair fee (cash)$20,000 Additional to board retainer
Compensation Committee member fee (cash)$7,500
Cash fees earned (2024 actual)$67,500 Matches policy (40,000 + 20,000 + 7,500)

Notes:

  • Independent director cash fees are subject to plan-imposed annual limits; non-independent, non-employee directors did not receive retainers in 2024 .

Performance Compensation

Equity ElementGrant/StatusValue/UnitsVesting/Terms
Annual RSU grant (2024)Granted to each independent director at 2024 annual meeting$25,800 grant date fair value; 20,000 RSUs outstanding for Ms. Demski as of 12/31/24 Vests in full on first anniversary of grant date per policy
Initial option grant (on appointment)Option sized at 0.20% of shares outstanding at grant (per director policy and appointment 8‑K)Number at grant based on 0.20% policy; 56,683 options outstanding as of 12/31/24 1/3 vests on 1st anniversary, remainder monthly over next 24 months (subject to service)

Additional notes:

  • 2024 annual equity program for directors used fixed RSU grants of 20,000 shares (~0.05% of outstanding at that time) .
  • No performance-based metrics are disclosed for director equity; awards are time-vested .

Other Directorships & Interlocks

  • Public company boards: Service disclosed at Chimerix, Equillium, and ADMA (see External Roles above) .
  • TKNO control and committee composition: Telegraph Hill Partners (THP) controls a majority of TKNO’s voting power; TKNO utilizes “controlled company” exemptions. The Compensation Committee includes a non‑independent member (Paul Grossman), while Ms. Demski and Ms. Robertson are independent; the Audit Committee remains fully independent and chaired by Ms. Demski .
  • Related-party transactions: Upon appointment, TKNO disclosed no related‑party transactions for Ms. Demski under Item 404(a) of Regulation S‑K .

Expertise & Qualifications

  • Audit Committee financial expert; able to read and understand fundamental financial statements .
  • Extensive finance and operating experience, including roles as CFO and COO; public company board leadership experience (chair, lead independent director, audit chair, compensation member) .

Equity Ownership

Ownership ItemValue
Shares beneficially owned (4/22/2025)33,065 shares; less than 1% of outstanding
Shares outstanding basis53,440,810 shares outstanding (ownership table basis)
Options outstanding (12/31/2024)56,683 options
RSUs outstanding (12/31/2024)20,000 RSUs
Hedging/pledgingCompany policy prohibits directors from hedging or pledging TKNO securities

Governance Assessment

Strengths

  • Independent director with deep finance expertise; chairs a fully independent Audit Committee and is designated an “Audit Committee financial expert” .
  • Demonstrated engagement: board met 9 times in 2024 and each director attended at least 75% of applicable meetings; Audit Committee met 5 times and issued its report recommending inclusion of audited financials .
  • Director equity structure mixes cash and equity; 2024 RSUs vest after one year, aligning with shareholder interests without excessive guarantees .
  • No related‑party transactions disclosed for Ms. Demski at appointment; indemnity agreement in standard form was executed .

Risks/Watch Items

  • Controlled company structure with only three independent directors (Demski, Robertson, Vos) out of eight, and use of Nasdaq “controlled company” exemptions limits independent oversight breadth .
  • Compensation Committee includes a non‑independent member (Paul Grossman), which can raise perceived conflicts despite Ms. Demski’s independent presence on the committee .
  • Director equity awards are time‑based (not performance‑based), which may be viewed as less stringent from a pay‑for‑performance perspective; however, this is typical for non‑employee directors .